Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

This study has been completed.
Sponsor:
Information provided by:
Asociación para Evitar la Ceguera en México
ClinicalTrials.gov Identifier:
NCT00407121
First received: December 1, 2006
Last updated: NA
Last verified: December 2006
History: No changes posted
  Purpose

Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.


Condition Intervention Phase
Vogt Koyanagi Harada Disease
Serpiginous Choroiditis
Multifocal Choroiditis
Drug: Bevacizumab
Procedure: Intravitreal Injection of Bevacizumab
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation

Resource links provided by NLM:


Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:
  • Best corrected visual acuity
  • Retinal thickness by OCT
  • Leakage in Fluorescein angiogram

Study Start Date: August 2006
Estimated Study Completion Date: November 2006
  Eligibility

Ages Eligible for Study:   25 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical Diagnose
  • Patient Consent
  • Chronic stage of inflammation

Exclusion Criteria:

  • only eye
  • age lower than 30 yo.
  • Systemic condition
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00407121

Locations
Mexico
Asociacion para Evitar la Ceguera en Mexico
Mexico, Distrito Federal, Mexico, 04030
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Investigators
Principal Investigator: Veronica Kon-Jara, MD Asociación para Evitar la Ceguera en México
Study Chair: LuzElena Concha-Del Rio, MD Asociación para Evitar la Ceguera en México
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00407121     History of Changes
Other Study ID Numbers: APEC-0025
Study First Received: December 1, 2006
Last Updated: December 1, 2006
Health Authority: National Institute of Public Health: Health Secretariat

Keywords provided by Asociación para Evitar la Ceguera en México:
Neovascular Membrane
Uveitis
Bevacizumab

Additional relevant MeSH terms:
Choroiditis
Chorioretinitis
Uveitis
Uveomeningoencephalitic Syndrome
Choroid Diseases
Uveal Diseases
Eye Diseases
Uveitis, Posterior
Panuveitis
Retinitis
Retinal Diseases
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Meningoencephalitis
Central Nervous System Infections
Central Nervous System Diseases
Autoimmune Diseases
Immune System Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 23, 2014